# ACE527 Safety and Immunogenicity Study

> **NCT00901654** · PHASE1 · COMPLETED · sponsor: **TD Vaccines A/S** · enrollment: 36 (estimated)

## Conditions studied

- Enterotoxigenic E. Coli (ETEC) Infection

## Interventions

- **BIOLOGICAL:** ACE527 vaccine
- **BIOLOGICAL:** Placebo vaccine

## Key facts

- **NCT ID:** NCT00901654
- **Lead sponsor:** TD Vaccines A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2010-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00901654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00901654, "ACE527 Safety and Immunogenicity Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00901654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*